Celcuity CEO to Present at Key Healthcare Conferences in March
Event summary
- Celcuity CEO Brian Sullivan to present at TD Cowen Healthcare Conference on March 4, 2026
- Sullivan to participate in Leerink Global Healthcare Conference on March 10, 2026
- Company to host one-on-one investor meetings at Jefferies Biotech Summit on March 11, 2026
- Webcasts available for both conferences, replays posted post-event
- Celcuity's lead drug gedatolisib in Phase 3 trials for breast cancer and Phase 1/2 for prostate cancer
The big picture
Celcuity's participation in these high-profile investor conferences comes as it advances its lead drug gedatolisib through critical clinical trials. The company is operating in a competitive oncology space where differentiation through mechanism of action and clinical outcomes will be key. Success in these trials could position Celcuity as a significant player in targeted cancer therapies, particularly for HR+/HER2- breast cancer and metastatic prostate cancer.
What we're watching
- Clinical Progress
- The pace at which Celcuity advances its Phase 3 VIKTORIA trials will determine investor sentiment
- Market Positioning
- Whether Celcuity can differentiate gedatolisib in the competitive PI3K/AKT/mTOR inhibitor space
- Investor Perception
- How conference presentations impact investor confidence in Celcuity's pipeline and execution
Related topics